Literature DB >> 6703752

Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice.

J P Callen.   

Abstract

Eighty-two patients, with pathologically confirmed cutaneous leukocytoclastic vasculitis (LV), were seen in private dermatology offices. An analysis of the group was made to determine the relationship of cutaneous to systemic disease, the incidence and importance of laboratory abnormalities, and the prognosis of patients with cutaneous LV and to compare these results with previously published data derived from medical centers. Systemic disease occurred in 42 patients, but was transient and mild in most. Two patients died as a result of systemic vasculitis. The morphologic type of skin lesions most commonly found were palpable purpura (51 patients), urticarial-like lesions (17 patients), ulcers (eight patients), erythematous plaques (five patients), and/or nodules (five patients). Possible causative agents could be identified in 38 patients and included drugs (eight patients), infections (eight patients), or collagen vascular disease (17 patients). The course of the disorder was acute in 46 cases, chronic in 24, and recurrent in 12. The patients described herein fared better and had less significant systemic disease than those described in studies from medical centers. The data support the usual benign course of cutaneous LV as seen by practitioners despite frequent systemic symptoms or findings.

Entities:  

Mesh:

Year:  1984        PMID: 6703752     DOI: 10.1001/archderm.120.4.484

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  26 in total

1.  Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case.

Authors:  Gunveen Singh; Tim Hodgson; David E Clarke
Journal:  Perm J       Date:  2016-11-18

2.  Leucocytoclastic vasculitic neuropathy diagnosed by biopsy of normal appearing skin.

Authors:  Y Yamanaka; A Hiraga; K Arai; M Mori; K Kanai; T Hattori; S Kuwabara; T Oide; T Tanizawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

3.  Leukocytoclastic vasculitis drug reaction to certolizumab pegol.

Authors:  Meghan Woody; Donald Warren; Laura Speck; Julie Jackson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

Review 4.  Cutaneous manifestations in systemic vasculitis.

Authors:  I Decleva; A V Marzano; M Barbareschi; E Berti
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

5.  Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota.

Authors:  Amrita Arora; David A Wetter; Tania M Gonzalez-Santiago; Mark D P Davis; Christine M Lohse
Journal:  Mayo Clin Proc       Date:  2014-06-27       Impact factor: 7.616

6.  Severe leukocytoclastic vasculitis secondary to the use of a naproxen and requiring amputation: a case report.

Authors:  Keri Brown; Jeanine Martin; Susan Zito
Journal:  J Med Case Rep       Date:  2010-07-01

Review 7.  Cutaneous leukocytoclastic vasculitis with cervical tuberculous lymphadenitis: a case report and literature review.

Authors:  Hee Man Kim; Yong-Beom Park; Ho Young Maeng; Soo-Kon Lee
Journal:  Rheumatol Int       Date:  2006-07-08       Impact factor: 2.631

8.  Sequential Use of Hyperbaric Oxygen, Synthetic Skin Substitute and Skin Grafting in the Treatment of a Refractory Vasculitic Ulcer.

Authors:  Gökhan Akcali; Günalp Uzun; Abdül Kerim Yapici; Şenol Yildiz
Journal:  J Am Coll Clin Wound Spec       Date:  2015-03-06

9.  Leucocytoclastic vasculitis as presenting feature of primary Sjögren's syndrome.

Authors:  H M Markusse; M Schoonbrood; M Oudkerk; S C Henzen-Logmans
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

10.  Ulcerative colitis presenting as leukocytoclastic vasculitis of skin.

Authors:  Sabiye Akbulut; Ersan Ozaslan; Firdevs Topal; Levent Albayrak; Burcak Kayhan; Cumali Efe
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.